Active substance
Iothalamate
- US FDA 9
- Safety 3
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CYSTO-CONRAY | 43% | solution · intravesical, ureteral | LIEBEL-FLARSHEIM | Prescription | 17 Apr 1972 |
| CYSTO-CONRAY II | 17.2% | solution · intravesical | LIEBEL-FLARSHEIM | Prescription | 17 Apr 1972 |
| CONRAY | 60% | injectable · injection | LIEBEL-FLARSHEIM | Discontinued | 16 Aug 1962 |
| CONRAY 43 | 43% | injectable · injection | LIEBEL-FLARSHEIM | Discontinued | 16 Aug 1962 |
| CONRAY 400 | 66.8% | injectable · injection | MALLINCKRODT | Discontinued | 30 Sep 1963 |
| VASCORAY | 52%;26% | injectable · injection | MALLINCKRODT | Discontinued | 26 Jan 1971 |
| CONRAY 30 | 30% | injectable · injection | LIEBEL-FLARSHEIM | Discontinued | 6 Aug 1971 |
| CONRAY 325 | 54.3% | injectable · injection | MALLINCKRODT | Discontinued | 7 Sep 1976 |
| ANGIO-CONRAY | 80% | injectable · injection | MALLINCKRODT | Discontinued | 26 Apr 1996 |
Safety signals and safety-related labeling changes
- US FDA 26 Apr 2023 CONRAY — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Apr 2023 CONRAY 43 — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Apr 2017 CONRAY 30 — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.